Literature DB >> 2761577

The absence of a relation between the periconceptional use of vitamins and neural-tube defects. National Institute of Child Health and Human Development Neural Tube Defects Study Group.

J L Mills1, G G Rhoads, J L Simpson, G C Cunningham, M R Conley, M R Lassman, M E Walden, O R Depp, H J Hoffman.   

Abstract

Whether taking multivitamins or folate around the time of conception can reduce a woman's risk of having a child with a neural-tube defect is controversial. To investigate this question, we examined the periconceptional use of vitamin supplements by women who had a conceptus with a neural-tube defect (n = 571), women who had had a stillbirth or a conceptus with another malformation (n = 546), and women who had had a normal conceptus (n = 573). Women with conceptuses with neural-tube defects were identified either prenatally or postnatally and were matched to control mothers for gestational age. To minimize recall bias, we interviewed nearly all the women within five months of the diagnosis of a birth defect or the birth of the infant (mean, 84 days); information on vitamin use was obtained by an interviewer who was unaware of the outcome of pregnancy. The rate of periconceptional multivitamin use among the mothers of infants with neural-tube defects (15.8 percent) was not significantly different from the rate among mothers in either the abnormal or the normal control group (14.1 percent and 15.9 percent, respectively). After adjustment for potential confounding factors, the odds ratio for having an infant with a neural-tube defect among women classified as having had full supplementation with multivitamins was 0.95 as compared with the mothers of the abnormal infants (95 percent confidence interval, 0.78 to 1.14) and 1.00 as compared with the mothers of normal infants (95 percent confidence interval, 0.83 to 1.20). There were no differences among the groups in the use of folate supplements. The adjusted odds ratio for having an infant with a neural-tube defect among those receiving the recommended daily allowance of folate was 0.97 as compared with the mothers of abnormal infants (95 percent confidence interval, 0.79 to 1.18) and 0.98 as compared with the mothers of normal infants (95 percent confidence interval, 0.80 to 1.20). We conclude that the periconceptional use of multivitamins or folate-containing supplements by American women does not decrease the risk of having an infant with a neural-tube defect.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2761577     DOI: 10.1056/NEJM198908173210704

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  25 in total

Review 1.  Preconception care: a systematic review.

Authors:  Carol C Korenbrot; Alycia Steinberg; Catherine Bender; Sydne Newberry
Journal:  Matern Child Health J       Date:  2002-06

2.  The impact of prenatal diagnosis on neural tube defect (NTD) pregnancy versus birth incidence in British Columbia.

Authors:  Margot I Van Allen; Erin Boyle; Paul Thiessen; Deborah McFadden; Douglas Cochrane; G Keith Chambers; Sylvie Langlois; Patricia Stathers; Beverly Irwin; Elizabeth Cairns; Patrick MacLeod; Marie-France Delisle; Soo-Hong Uh
Journal:  J Appl Genet       Date:  2006       Impact factor: 3.240

3.  Folic acid and prevention of neural tube defects.

Authors:  N T Glanville; H W Cook
Journal:  CMAJ       Date:  1992-01-01       Impact factor: 8.262

4.  Periconceptional vitamin supplementation and neural tube defects; evidence from a case-control study in Western Australia and a review of recent publications.

Authors:  C Bower; F J Stanley
Journal:  J Epidemiol Community Health       Date:  1992-04       Impact factor: 3.710

5.  California's public health policy on preventing neural tube defects by folate supplementation.

Authors:  G C Cunningham
Journal:  West J Med       Date:  1995-03

6.  Folate to prevent neural tube defects.

Authors:  J P Welch
Journal:  CMAJ       Date:  1995-04-01       Impact factor: 8.262

Review 7.  Fetal drug therapy.

Authors:  M I Evans; P G Pryde; A Reichler; M Bardicef; M P Johnson
Journal:  West J Med       Date:  1993-09

Review 8.  The search for genetic polymorphisms in the homocysteine/folate pathway that contribute to the etiology of human neural tube defects.

Authors:  Anne M Molloy; Lawrence C Brody; James L Mills; John M Scott; Peadar N Kirke
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2009-04

9.  Neural tube defects and maternal folate intake among pregnancies conceived after folic acid fortification in the United States.

Authors:  Bridget S Mosley; Mario A Cleves; Anna Maria Siega-Riz; Gary M Shaw; Mark A Canfield; D Kim Waller; Martha M Werler; Charlotte A Hobbs
Journal:  Am J Epidemiol       Date:  2008-10-25       Impact factor: 4.897

10.  Recommendations on the use of folic acid supplementation to prevent the recurrence of neural tube defects. Clinical Teratology Committee, Canadian College of Medical Geneticists.

Authors:  M I Van Allen; F C Fraser; L Dallaire; J Allanson; D R McLeod; E Andermann; J M Friedman
Journal:  CMAJ       Date:  1993-11-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.